Home » MediciNova Reports Results of a Phase IIb Trial of MN-221 in Asthma Exacerbations
MediciNova Reports Results of a Phase IIb Trial of MN-221 in Asthma Exacerbations
MediciNova and the Jasdaq Market of the Osaka Securities Exchange, announced preliminary results from a hospital emergency department-based Phase IIb clinical trial evaluating MN-221 in patients with acute exacerbations of asthma did not statistically meet the primary endpoint, improvement in FEV1, or forced expiratory volume, in one second, compared to placebo.
RTT News
RTT News
Upcoming Events
-
04Apr
-
11Apr
-
14Apr
-
25Apr
-
14May